CD99 engagement: An effective therapeutic strategy for Ewing tumors

K. Scotlandi, N. Baldini, V. Cerisano, M. C. Manara, S. Benini, M. Serra, P. L. Lollini, P. Nanni, G. Nicoletti, G. Bernard, A. Bernard, P. Picci

Research output: Contribution to journalArticlepeer-review


CD99 is a M(r) 32,000 transmembrane molecule that shows a high level of expression on cells of the hemopoietic system as well as on Ewing tumor cells. Within the hematopoietic system, CD99 has been implicated in cell adhesion and cell death, participating in this way in the differentiation of T-cell precursors. In this study, we demonstrate that engagement of CD99 significantly inhibits the in vitro and in vivo growth ability of Ewing tumor cells by delivering an apoptotic stimulus and reducing the malignant potential of these cells. Moreover, we show that anti-CD99 monoclonal antibodies may be advantageously used in association with conventional anticancer agents. These results provide a novel entry site for therapeutic intervention, which may have application in the care of patients with Ewing tumor, and warrant additional studies to clarify the molecular mechanisms activated by CD99 engagement.

Original languageEnglish
Pages (from-to)5134-5142
Number of pages9
JournalCancer Research
Issue number18
Publication statusPublished - Sep 15 2000

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'CD99 engagement: An effective therapeutic strategy for Ewing tumors'. Together they form a unique fingerprint.

Cite this